Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
June 17, 2024 09:45 ET
|
FN Media Group LLC
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - According to a report from Mordor Intelligence the Acute Myeloid Leukemia Market size is estimated at USD 1.83...
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
June 17, 2024 09:00 ET
|
FN Media Group LLC
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by...
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference
May 30, 2024 08:00 ET
|
Compass Therapeutics
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to...
Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
May 23, 2024 17:05 ET
|
Compass Therapeutics
CTX-471, a novel anti-CD137 agonist antibody, demonstrated anti-tumor activity in the Company’s Phase 1 Dose Escalation and Dose Expansion, first-in-human monotherapy study in patients with metastatic...
Compass Therapeutics to Participate in the Stifel Targeted Oncology Days
April 10, 2024 08:00 ET
|
Compass Therapeutics
BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
eFFECTOR Initiates Dosing of eFT508 (tomivosertib) in a Phase 2 Add-on (CPI-A) Trial in Combination with Checkpoint Inhibitors to Treat Patients with Insufficient Response to Checkpoint Inhibitors Alone
July 27, 2018 07:30 ET
|
eFFECTOR Therapeutics
SAN DIEGO, July 27, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that it...
eFFECTOR Initiates Dosing of eFT508 in Phase 2 Expansion of Clinical Trial in Aggressive Form of Non-Hodgkin’s Lymphoma
June 06, 2018 07:30 ET
|
eFFECTOR Therapeutics
SAN DIEGO, June 06, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that it...
eFFECTOR Initiates Randomized Dosing in Phase 2 Checkpoint Combination Trial of eFT508 and Avelumab in Colorectal Cancer
May 11, 2018 07:30 ET
|
eFFECTOR Therapeutics
SAN DIEGO, May 11, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that it...
eFFECTOR Publishes the Design and Profile of eFT508 in Peer Reviewed Journal of Medicinal Chemistry
April 26, 2018 07:30 ET
|
eFFECTOR Therapeutics
SAN DIEGO, April 26, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that...
eFFECTOR Presents Data on the Discovery and Structure of eFT226, a Novel Inhibitor of eIF4A, at the AACR 2018 Annual Meeting
April 16, 2018 08:00 ET
|
eFFECTOR Therapeutics
SAN DIEGO, April 16, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced a...